Nyxoah SA announced the upcoming release of efficacy and safety data from the DREAM US pivotal study on the Genio neurostimulation system for obstructive sleep apnea (OSA). The results are expected by early April, according to the company’s fourth-quarter and full-year 2023 … [Read more...]
Is Neurostimulation Cost-Effective for Mild Sleep Apnea?
A new exploratory analysis finds that using neuromuscular electrical stimulation as a treatment option for patients with mild obstructive sleep apnea may be cost-effective. Recent estimates suggest that 55 million adults in the United States have obstructive sleep apnea, with … [Read more...]